Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16917646 | 0.92 | — | — | |
| SCHEMBL3132513 | 0.92 | — | — | |
| SCHEMBL3132514 | 0.92 | — | — | |
| SCHEMBL16063270 | 0.92 | — | — | |
| SCHEMBL13604717 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL9724372 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL13604747 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL14432216 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL2632246 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL821048 | 0.80 | TSHR (0.46) | ALDH1A1TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605735-B2 | Ruthenium complex, process for producing the same and process for producing thin film | TOSOH CORPORATION (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20030088116-A1 | RUTHENIUM COMPLEX, PROCESS FOR PRODUCING THE SAME AND PROCESS FOR PRODUCING THIN FILM | TOSOH CORPORATION | 2003-05-08 | — | — | US | disclosed |
| EP-1293509-A2 | Ruthenium complex, process for producing the same and process for producing thin film | Tosoh Corporation (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088116-A1 | RUTHENIUM COMPLEX, PROCESS FOR PRODUCING THE SAME AND PROCESS FOR PRODUCING THIN FILM | EMG1, C5, VAMP7 | CNR2 2718/4885CNR1 3137/4885PPARG 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.